表紙
市場調査レポート

非小細胞肺癌 (NSCLC):パイプライン製品の分析

Non-Small Cell Lung Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232838
出版日 ページ情報 英文 2025 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
非小細胞肺癌 (NSCLC):パイプライン製品の分析 Non-Small Cell Lung Cancer - Pipeline Review, H1 2016
出版日: 2016年06月28日 ページ情報: 英文 2025 Pages
概要

非小細胞肺癌 (NSCLC) は、最もよく見られる肺癌の一種です。肺の組織や気道の細胞から発生する癌(悪性腫瘍)です。喫煙は、肺癌の最も多い原因です。肺癌の症状は、通常、後期に見られます。兆候と症状には、持続性の咳、呼吸困難、息切れ、恒常的な胸部の痛みや不快感、血痰、疲労、虚弱、意図しない体重減少などの症状が見られます。治療には、投薬、化学療法、生活スタイルの変更などが含まれます。

当レポートでは、非小細胞肺癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

非小細胞肺癌の概要

治療薬の開発

非小細胞肺癌:企業で開発中の治療薬

非小細胞肺癌:大学/機関で研究中の治療薬

非小細胞肺癌:パイプライン製品の概況

非小細胞肺癌:企業で開発中の製品

非小細胞肺癌:大学/機関で研究中の製品

非小細胞肺癌の治療薬開発に従事している企業

非小細胞肺癌:治療薬の評価

薬剤プロファイル

非小細胞肺癌:休止中のプロジェクト

非小細胞肺癌:開発が中止された製品

非小細胞肺癌:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7954IDB

Summary

Global Markets Direct's, 'Non-Small Cell Lung Cancer - Pipeline Review, H1 2016', provides an overview of the Non-Small Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
  • The report reviews pipeline therapeutics for Non-Small Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Non-Small Cell Lung Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Non-Small Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Non-Small Cell Lung Cancer Overview
  • Therapeutics Development
  • Non-Small Cell Lung Cancer - Therapeutics under Development by Companies
  • Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
  • Non-Small Cell Lung Cancer - Pipeline Products Glance
  • Non-Small Cell Lung Cancer - Products under Development by Companies
  • Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes
  • Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
  • Non-Small Cell Lung Cancer - Therapeutics Assessment
  • Drug Profiles
  • Non-Small Cell Lung Cancer - Dormant Projects
  • Non-Small Cell Lung Cancer - Discontinued Products
  • Non-Small Cell Lung Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Non-Small Cell Lung Cancer, H1 2016
  • Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Development by Companies, H1 2016 (Contd..18)
  • Number of Products under Development by Companies, H1 2016 (Contd..19)
  • Number of Products under Development by Companies, H1 2016 (Contd..20)
  • Number of Products under Development by Companies, H1 2016 (Contd..21)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Development by Companies, H1 2016 (Contd..27)
  • Products under Development by Companies, H1 2016 (Contd..28)
  • Products under Development by Companies, H1 2016 (Contd..29)
  • Products under Development by Companies, H1 2016 (Contd..30)
  • Products under Development by Companies, H1 2016 (Contd..31)
  • Products under Development by Companies, H1 2016 (Contd..32)
  • Products under Development by Companies, H1 2016 (Contd..33)
  • Products under Development by Companies, H1 2016 (Contd..34)
  • Products under Development by Companies, H1 2016 (Contd..35)
  • Products under Development by Companies, H1 2016 (Contd..36)
  • Products under Development by Companies, H1 2016 (Contd..37)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Altimmune, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corporation, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Amgen Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by AndroScience Corporation, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by APO-T B.V., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by ArQule, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by ATLAB Pharma SAS, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Batu Biologics, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by BeiGene, Ltd., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Benitec Biopharma Limited, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Beta Pharma, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by BIOCAD, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corporation, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by CanBas Co., Ltd., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellectis S.A., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellmid Limited, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Celltrion, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cipla Ltd., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by CTI BioPharma Corp., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by CureVac GmbH, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Debiopharm International SA , H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma, LLC, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by DiNonA Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Domainex Limited, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by DormaTarg, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by EirGenix Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Endocyte, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by EntreChem, S.L., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eudendron S.r.l., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

List of Figures

  • Number of Products under Development for Non-Small Cell Lung Cancer, H1 2016
  • Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top